Quantification of cytomegalovirus DNA in peripheral blood leukocytes by a branched-DNA signal amplification assay

Journal of Clinical Microbiology

Volumn 35, Issue 11, 1997, Pages 2740-2744

  Chernoff, David N ^a   Miner, Richard C ^b   Hoo, Bradley S ^a   Shen, Lu Ping ^a   Kelso, Reed J ^a   Jekic McMullen, Dragana ^b   Lalezari, Jacob P ^b   Chou, Sunwen ^c   Drew, W Lawrence ^b   Kolberg, Janice A ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS ANTIGEN; VIRUS DNA;

ARTICLE; BLOOD DONOR; BLOOD LEVEL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DNA DETERMINATION; GENE AMPLIFICATION; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; LEUKOCYTE; MAJOR CLINICAL STUDY; MONONUCLEAR CELL; PRACTICE GUIDELINE; PRIORITY JOURNAL;

CUCUMBER MOSAIC VIRUS; CYTOMEGALOVIRUS; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0030760598     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/jcm.35.11.2740-2744.1997     Document Type: Article

References (38)

1. Arribas, J. R., D. B. Clifford, C. J. Fichtenbaum, D. L. Commins, W. G. Powderly, and G. A. Storch. 1995. Level of cytomegalovirus (CMV) DNA in cerebrospinal fluid of subjects with AIDS and CMV infection of the central nervous system. J. Infect. Dis. 172:527-531.
2. Biron, K. K., S. C. Stanat, J. B. Sorrell, J. A. Fife, P. M. Keller, C. U. Lambe, and D. J. Nelson. 1985. Metabolic activation of the nucleoside analog 9-{[2-hydroxy-1-(hydroxymethly)ethoxy]methyl}guanine in human diploid fibroblasts infected with human cytomegalovirus. Proc. Natl. Acad. Sci. USA 82:2473-2477.
3. Bogner, E., M. Reschke, B. Reis, T. Mockenhaupt, and K. Radsak. 1993. Identification of the gene product encoded by ORF UL56 of the human cytomegalovirus genome. Virology 196:290-293.
4. Boivin, G., S. Chou, M. R. Quirk, A. Erice, and M. C. Jordan. 1996. Detection of ganciclovir resistance mutations and quantitation of cytomegalovirus (CMV) DNA in leukocytes of patients with fatal disseminated CMV disease. J. Infect. Dis. 173:523-528.
5. Chou, S., and K. M. Dennison. 1991. Analysis of interstrain variation in cytomegalovirus glycoprotein B sequences encoding neutralization-related epitopes. J. Infect. Dis. 163:1229-1234.
6. Chou, S., S. Guentzel, K. R. Michels, R. C. Miner, and W. L. Drew. 1995. Frequency of UL97 phosphotransferase mutations related to ganciclovir resistance in clinical cytomegalovirus isolates. J. Infect. Dis. 172:239-242.
7. Collins, M. L., C. Zayati, J. J. Detmer, B. Daly, J. A. Kolberg, T. A. Cha, B. D. Irvine, J. Tucker, and M. S. Urdea. 1995. Preparation and characterization of RNA standards for use in quantitative branched DNA hybridization assays. Anal. Biochem. 226:120-129.
8. Davis, G. L., J. Y. Lau, M. S. Urdea, P. D. Neuwald, J. C. Wilber, K. Lindsay, R. P. Perrillo, and J. Albrecht. 1994. Quantitative detection of hepatitis C virus RNA with a solid-phase signal amplification method: definition of optimal conditions for specimen collection and clinical application in interferon-treated patients. Hepatology 19:1337-1341.
9. Detmer, J., R. Lagier, J. Flynn, C. Zayati, J. Kolberg, M. Collins, M. Urdea, and R. Sánchez-Pescador. 1996. Accurate quantification of HCV RNA from all HCV genotypes using branched DNA (bDNA) technology. J. Clin. Microbiol. 34:901-907.
10. Dewar, R. L., H. C. Highbarger, M. D. Sarmiento, J. A. Todd, M. B. Vasudevachari, R. J. Davey, J. A. Kovacs, N. P. Salzman, H. C. Lane, and M. S. Urdea. 1994. Application of branched DNA signal amplification to monitor human immunodeficiency virus type 1 burden in human plasma. J. Infect. Dis. 170:1172-1179.
11. Drew, W. L., D. Ives, J. P. Lalezari, C. Crumpackcr, S. E. Follansbee, S. A. Spector, C. A. Benson, D. N. Friedberg, L. Hubbard, M. J. Stempien, A. Shadman, and W. Buhles. 1995. Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. Syntex Cooperative Oral Ganciclovir Study Group. N. Engl. J. Med. 333:615-620.
12. Drew, W. L., R. C. Miner, D. F. Busch, S. E. Follansbee, J. Gullett, S. G. Mehalko, S. M. Gordon, W. F. Owen, Jr., T. R. Matthews, W. C. Buhles, and B. DeArmond. 1991. Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection. J. Infect. Dis. 163:716-719.
13. Drouet, E., R. Colimon, S. Michelson, N. Fourcade, A. Niveleau, C. Ducerf, A. Boibieux, M. Chevallier, and G. Denoyel. 1995. Monitoring levels of human cytomegalovirus DNA in blood after liver transplantation. J. Clin. Microbiol. 33:389-394.
14. Einsele, H., G. Ehninger, H. Hebart, K. M. Wittkowski, U. Schuler, G. Jahn, P. Mackes, M. Herter, T. Klingebiel, J. Loffler, S. Wagner, and C. A. Müller. 1995. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood 86:2815-2820.
15. Flood, J., W. L. Drew, R. Miner, D. Jekic-McMullen, L.-P. Shen, J. Kolberg, J. Garvey, S. Follansbee, and M. Poscher. 1997. Detection of cytomegalovirus (CMV) polyradiculopathy and documentation of in vivo anti-CMV activity in cerebrospinal fluid using branched DNA signal amplification and CMV antigen assays. J. Infect. Dis. 176:348-352.
16. Gerna, G., M. Furione, F. Baldanti, and A. Sarasini. 1994. Comparative quantitation of human cytomegalovirus DNA in blood leukocytes and plasma of transplant and AIDS patients. J. Clin. Microbiol. 32:2709-2717.
17. Graybill, F. 1976. Theory and application of the linear model, p. 606-648. Prindle, Weber and Schmidt, Boston, Mass.
18. Hendricks, D. A., B. S. Stowe, B. S. Hoo, J. Kolberg, B. S. Irvine, P. D. Neuwald, M. S. Urdea, and R. P. Perillo. 1995. Quanitation of HBV DNA in human serum using a branched DNA (bDNA) signal amplification assay. Am. J. Clin. Pathol. 104:537-546.
19. Hibberd, P. L., N. E. Tolkoff-Rubin, D. Conti, F. Stuart, J. R. Thistlethwaite, J. F. Neylan, D. R. Snydman, R. Freeman, M. I. Lorber, and R. H. Rubin. 1996. Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recipients. Ann. Intern. Med. 123:18-26.
20. Ho, D. D., A. U. Neumann, A. S. Perelson, W. Chen, J. M. Leonard, and M. Markowitz. 1995. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373:123-126.
21. Kühn, J. E., T. Wendland, P. Schafer, K. Mohring, U. Wieland, M. Elgas, and H. J. Eggers. 1994. Monitoring of renal allograft recipients by quantitation of human cytomegalovirus genomes in peripheral blood leukocytes. J. Med. Virol. 44:398-405.
22. Lalezari, J. P., W. L. Drew, E. Glutzer, C. James, D. Miner, J. Flaherty, P. E. Fisher, K. Cundy, J. Hannigan, J. C. Martin, and H. S. Jaffe. 1995. (S)-1-[3-Hydroxy-2-(phosphonylmethoxy)propyl]cytosine (cidofovir): results of a phase I/II study of a novel antiviral nucleotide analogue. J. Infect. Dis. 171:788-796.
23. Mañez, R., S. Kusne, C. Rinaldo, J. M. Aguado, K. St. George, P. Grossi, B. Frye, J. J. Fung, and G. D. Ehrlich. 1996. Time to detection of cytomegalovirus (CMV) DNA in blood leukocytes is a predictor for the development of CMV disease in CMV-seronegative recipients of allografts from CMV-seropositive donors following liver transplantation. J. Infect. Dis. 173:1072-1076.
24. McCutchan, J. A. 1995. Clinical impact of cytomegalovirus infections of the nervous system in patients with AIDS. Clin. Infect. Dis. 21(Suppl. 2):S196-S201.
25. Mellors, J. W., C. R. Rinaldo, Jr., P. Gupta, R. M. White, J. A. Todd, and L. A. Kingsley. 1996. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 272:1167-1170.
26. National Committee for Clinical Laboratory Standards. 1992. Evaluation of precision, performance of clinical chemistry devices; tenative guidelines, vol. 12. NCCLS publication EP5-T2. National Committee for Clinical Laboratory Standards, Villanova, Pa.
27. Nolte, F. S., R. K. Emmens, C. Thurmond, P. S. Mitchell, C. Pascuzzi, S. M. Devine, R. Saral, and J. R. Wingard. 1995. Early detection of human cytomegalovirus viremia in bone marrow transplant recipients by DNA amplification. J. Clin. Microbiol. 33:1263-1266.
28. Pachl, C., J. A. Todd, D. G. Kern, P. J. Sheridan, S.-F. Fong, M. Stempien, B. Hoo, D. Besemer, T. Yeghiazarian, B. Irvine, J. Kolberg, R. Kokka, P. Neuwald, and M. S. Urdea. 1995. Rapid and precise quantification of HIV-1 RNA in plasma using a branched DNA (bDNA) signal amplification assay. J. Acquired Immune Defic. Syndr. Hum. Retrovirol. 8:446-454.
29. Polis, M. A., and H. Masur. 1995. Promising new treatments for cytomegalovirus retinitis. JAMA 273:1457-1459.
30. Pollard, R. B. 1988. Cytomegalovirus infections in renal, heart, heart-lung, and liver transplantation. Pediatr. Infect. Dis. J. 7(Suppl. 5):S97-S102.
31. Rasmussen, L., S. Morris, D. Zipeto, J. Fessel, R. Wolitz, A. Dowling, and T. C. Merigan. 1995. Quantitation of human cytomegalovirus DNA from peripheral blood cells of human immunodeficiency virus-infected patients could predict cytomegalovirus retinitis. J. Infect. Dis. 171:177-182.
32. Schmidt, C. A., H. Oettle, R. Peng, P. Neuhaus, G. Blumhardt, R. Lohmann, F. Wilborn, K. Osthoff, J. Oertel, H. Timm, and W. Seigert. 1995. Comparison of polymerase chain reaction from plasma and buffy coat with antigen detection and occurrence of immunoglobulin M for the demonstration of cytomegalovirus infection after liver transplantation. Transplantation 59: 1133-1138.
33. Singh, N., V. L. Yu, L. Mieles, M. M. Wagener, R. C. Miner, and T. Gayowski. 1994. High-dose acyclovir compared with short-course preemptive ganciclovir therapy to prevent cytomegalovirus disease in liver transplant recipients. A randomized trial. Ann. Intern. Med. 120:375-381.
34. Spaete, R. R., R. M. Thayer, W. S. Probert, F. R. Masiarz, S. H. Chamberlain, L. Rasmussen, T. C. Merigan, and C. Pachl. 1988. Human cytomegalovirus strain Towne glycoprotein B is processed by proteolytic cleavage. Virology 167:207-225.
35. Spector, S. A., K. Hsia, D. Wolf, M. Shinkai, and I. Smith. 1995. Molecular detection of human cytomegalovirus and determination of genotypic ganciclovir resistance in clinical specimens. Clin. Infect. Dis. 21(Suppl. 2):S170-S173.
36. Spector, S. A., G. F. McKinley, J. P. Lalezari, T. Samo, R. Andruczk, S. Follansbee, P. D. Sparti, D. V. Havlir, G. Simpson, W. Buhles, R. Wong, M. J. Stempien, and for the Roche Cooperative Oral Ganciclovir Study Group. 1996. Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. N. Engl. J. Med. 334:1491-1497.
37. The, T. H., A. P. van den Berg, M. C. Harmsen, W. van der Bij, and W. J. van Son. 1995. The cytomegalovirus antigenemia assay: a plea for standardization. Scand. J. Infect. Dis. Suppl. 99:25-29.
38. Weber, B., and H. W. Doerr. 1994. Diagnosis and epidemiology of transfusion-associated human cytomegalovirus infection: recent developments. Infusther. Transfusmed. 1:32-39.